Aditxt, Inc.

Nasdaq:ADTX

Pharmaceutical Preparations·RICHMOND, VA

CEO

Albanna Amro A.

Summary Financials

Revenue

$645,176

-30.9% YoY

FY 2024

Adj. EBITDA

-$25.6M

-3972.2% margin

FY 2024

Net Income

-$32.7M

-5068.5% margin

FY 2024

EPS (Diluted)

-$27038.26

FY 2024

Stock Price

$3.38

+626.7%

2026-03-09

52W Range

$0.41 – $1754.33

P/E Ratio

-0.0x

Market Cap

$1.9M

Cash

$97,102

FY 2024

Total Debt

$15.7M

FY 2024

Net Debt

$15.6M

FY 2024

Enterprise Value

$17.4M

Debt / EBITDA

-0.6x

FY 2024

EV / EBITDA

-0.7x

Employees

—

Revenue

$645,176

-30.9% YoY

FY 2024

Adj. EBITDA

-$25.6M

-3972.2% margin

FY 2024

Net Income

-$32.7M

-5068.5% margin

FY 2024

EPS (Diluted)

-$27038.26

FY 2024

Stock Price

$3.38

+626.7%

2026-03-09

52W Range

$0.41 – $1754.33

P/E Ratio

-0.0x

Market Cap

$1.9M

Cash

$97,102

FY 2024

Total Debt

$15.7M

FY 2024

Net Debt

$15.6M

FY 2024

Enterprise Value

$17.4M

Debt / EBITDA

-0.6x

FY 2024

EV / EBITDA

-0.7x

Employees

—